Skip to main content
UniHealth

Doctor search

Alexander Dimitrios Colevas, MD

Medical Oncology · Stanford

NPI 1588726558

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Colevas’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence C52711 · Current

Licensed to practise in California · since 2007 · expires 2026-11-30 · Johns Hopkins University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$121,939

Medicare paid this office $121,939 for 258 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)161$75,803$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$10,113$106
New patient visit (60+ min)44$7,159$163
Return visit (30+ min)46$5,974$83
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's116$5,842$15
See all 9 services
Every Original Medicare service billed
Long return visit (40+ min)161$75,803$126
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$10,113$106
New patient visit (60+ min)44$7,159$163
Return visit (30+ min)46$5,974$83
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's116$5,842$15
Initial hospital care with moderate level of medical decision making at least 75 minutes32$4,978$156
Diagnostic exam of voice box using a flexible endoscope43$3,666$61
Return visit (30+ min)18$3,201$110
Hospital discharge day management, more than 30 minutes11$1,154$105

Who their Medicare patients are

258 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 9% · Women 34% · Also on Medicaid 24% · Health risk score 2.45. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 68% · Coronary heart disease 29% · Diabetes 25% · Chronic kidney disease 24% · Cancer 22% · Atrial fibrillation 21% · Heart failure 19% · Depression 19% · COPD 16% · Stroke 10% · Dementia 6%.

The office billed $303,165, Medicare allowed $158,207 and paid $121,939; for 1,396 services of 16 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242581,396742.45$303,165$121,939
2023194681742.36$174,512$80,569
2022231871732.23$199,672$100,373
2021193712732.34$159,840$82,738
2020211995722.40$210,682$93,235
20193021,279722.43$242,265$117,440
20183131,291712.16$230,926$123,142
20172601,056722.14$274,612$99,545
2016233941722.40$275,084$90,160
2015275876712.20$265,569$85,864
2014212846711.97$242,008$80,170
2013200902712.07$271,498$82,653

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Original Medicare services billed in 2023
Long return visit (40+ min)115$48,434$132
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$9,763$110
Return visit (30+ min)45$6,865$90
New patient visit (60+ min)29$4,676$161
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,638$160
Diagnostic exam of voice box using a flexible endoscope39$2,774$63
Hospital discharge day management, more than 30 minutes11$1,178$107

2022: 6 services

Original Medicare services billed in 2022
Long return visit (40+ min)166$72,154$125
Return visit (30+ min)43$6,587$86
New patient visit (60+ min)37$6,251$169
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,407$176
Diagnostic exam of voice box using a flexible endoscope41$3,748$59
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$2,694$90

2021: 6 services

Original Medicare services billed in 2021
Long return visit (40+ min)137$58,006$129
Return visit (30+ min)55$6,718$85
New patient visit (60+ min)30$5,240$175
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$4,009$95
Diagnostic exam of voice box using a flexible endoscope39$3,162$60
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,637$188

2020: 8 services

Original Medicare services billed in 2020
Long return visit (40+ min)154$63,255$100
Return visit (30+ min)78$10,030$70
New patient visit (60+ min)34$5,204$153
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$4,304$98
Diagnostic exam of voice box using a flexible endoscope44$3,218$55
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,320$193
Return visit (30+ min)18$1,326$66
Short return visit (20+ min)13$731$49

2019: 7 services

Original Medicare services billed in 2019
Long return visit (40+ min)215$78,135$95
New patient visit (60+ min)64$9,422$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$8,584$94
Return visit (30+ min)49$6,460$69
Diagnostic exam of voice box using a flexible endoscope81$5,996$55
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,120$184
Hospital discharge day management, more than 30 minutes12$1,190$99

2018: 6 services

Original Medicare services billed in 2018
Long return visit (40+ min)214$80,426$96
New patient visit (60+ min)103$15,216$148
Diagnostic exam of voice box using a flexible endoscope86$7,584$58
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$7,115$94
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,548$182
Return visit (30+ min)43$4,521$70

2017: 7 services

Original Medicare services billed in 2017
Long return visit (40+ min)172$62,774$96
New patient visit (60+ min)83$11,982$144
Diagnostic exam of voice box using a flexible endoscope70$7,991$59
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$6,760$93
Initial hospital care with moderate level of medical decision making at least 75 minutes27$4,743$176
Return visit (30+ min)20$1,552$67
Hospital discharge day management, 30 minutes or less13$861$66

2016: 6 services

Original Medicare services billed in 2016
Long return visit (40+ min)154$59,100$95
New patient visit (60+ min)62$8,665$140
Diagnostic exam of voice box using a flexible endoscope57$6,395$70
Initial hospital care with moderate level of medical decision making at least 75 minutes31$5,768$180
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$5,555$93
Return visit (30+ min)17$1,611$70

2015: 8 services

Original Medicare services billed in 2015
Long return visit (40+ min)165$45,642$96
New patient visit (60+ min)74$10,860$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$10,514$93
Initial hospital care with moderate level of medical decision making at least 75 minutes34$6,331$181
Diagnostic exam of voice box using a flexible endoscope52$4,919$69
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,294$65
Return visit (30+ min)18$1,263$66
Hospital discharge day management, 30 minutes or less17$1,193$66

2014: 6 services

Original Medicare services billed in 2014
Long return visit (40+ min)144$48,094$94
New patient visit (60+ min)83$12,258$148
Diagnostic exam of voice box using a flexible endoscope62$7,865$71
Return visit (30+ min)29$3,411$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes11$3,142$92
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,338$180

2013: 7 services

Original Medicare services billed in 2013
Long return visit (40+ min)120$41,891$89
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$11,893$89
New patient visit (60+ min)58$8,324$144
Initial hospital care with moderate level of medical decision making at least 75 minutes36$6,280$174
Diagnostic exam of voice box using a flexible endoscope43$5,362$69
Return visit (30+ min)33$3,136$63
Hospital discharge day management, 30 minutes or less13$893$64

Medicaid work

$7,464 in 2024

Medicaid paid $7,464 for 120 billed services this clinician did in 2024, up to 21 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)120$7,464
Medicaid work by year
2024120121$7,464
2023207121$9,555
2022331224$14,383
2021214222$11,506
2020180121$8,532
2019327130$13,327
2018367128$19,814
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)207$9,555

2022

Largest Medicaid services in 2022
Long return visit (40+ min)317$13,429
1ST HOSP IP/OBS HIGH 7514$953

2021

Largest Medicaid services in 2021
Long return visit (40+ min)178$8,754
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES36$2,752

2020

Largest Medicaid services in 2020
Long return visit (40+ min)180$8,532

2019

Largest Medicaid services in 2019
Long return visit (40+ min)327$13,327

2018

Largest Medicaid services in 2018
Long return visit (40+ min)367$19,814

Drugs they prescribed that Part D paid

$1,217,616

Pharmacies billed $1,217,616 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 6% of their Part D prescriptions (21 of 374) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.

259 generic and fewer than 11 brand-name prescriptions · $1,217,616 in drug cost · 16 antibiotic prescriptions to 13 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Lenvima20$463,727$23,186
Eliquis19$10,835$570
Gabapentin22$590$27
Ondansetron15$562$37
Levothyroxine40$243$6
See all 7 drugs
Every Part D drug this clinician prescribed
Lenvima20$463,727$23,186
Eliquis19$10,835$570
Gabapentin22$590$27
Ondansetron15$562$37
Levothyroxine40$243$6
Dexamethasone16$208$13
Prochlorperazine Maleate11$132$12

Year by year

Part D prescribing by year
2024374876% (21)None$1,217,616
202316947NoneNone$498,877
202210146NoneNone$403,276
20217531None31%$136,672
202014343None36%$578,153
20192886710% (28)39%$916,409
201817654None19%$188,155
20172136115% (32)19%$170,924
20162176419% (42)18%$109,683
20152107216% (34)10%$35,799
20142535510% (26)9%$81,606
20132285916% (36)19%$112,871

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Part D drugs prescribed in 2023
Lenvima11$251,582$22,871
Levothyroxine29$281$10

2022: 2 drugs

Part D drugs prescribed in 2022
Lenvima13$280,678$21,591
Prednisone13$101$8

2020: 3 drugs

Part D drugs prescribed in 2020
Lenvima17$336,386$19,787
Ondansetron17$504$30
Prochlorperazine Maleate12$217$18

2019: 5 drugs

Part D drugs prescribed in 2019
Mekinist23$278,556$12,111
Lenvima14$263,132$18,795
Tafinlar22$223,224$10,147
Levothyroxine38$493$13
Ondansetron18$340$19

2018: 4 drugs

Part D drugs prescribed in 2018
Ondansetron18$410$23
Levothyroxine14$211$15
Dexamethasone14$143$10
Prochlorperazine Maleate14$66$5

2017: 4 drugs

Part D drugs prescribed in 2017
Ondansetron17$4,308$253
Levothyroxine19$314$17
Lorazepam17$56$3
Prochlorperazine Maleate12$55$5

2016: 5 drugs

Part D drugs prescribed in 2016
Hydrocodone-Acetaminophen11$546$50
Levothyroxine14$154$11
Gabapentin12$102$9
Prochlorperazine Maleate13$66$5
Lorazepam13$53$4

2015: 3 drugs

Part D drugs prescribed in 2015
Ondansetron17$919$54
Prochlorperazine Maleate12$64$5
Lorazepam14$52$4

2014: 7 drugs

Part D drugs prescribed in 2014
Enoxaparin29$14,248$491
Ondansetron25$595$24
Dexamethasone20$136$7
Prochlorperazine Maleate23$131$6
Levothyroxine11$119$11
Lorazepam19$83$4
Metoclopramide16$64$4

2013: 6 drugs

Part D drugs prescribed in 2013
Ondansetron11$382$35
Gabapentin15$377$25
Hydrocodone-Acetaminophen27$245$9
Levothyroxine18$199$11
Prochlorperazine Maleate11$91$8
Lorazepam11$48$4

Money from drug and device companies

$117 in 2025

Industry payments by year
202511None$117
202311None$92
202022$3,610$3,634

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Aveo PharmaceuticalsFotivda$117
1 payment
  • Meals for Fotivda · 2025-06-01 · $117
See the published payment
Every published payment
Aveo PharmaceuticalsMeals · 2025-06-01Fotivda$117
See earlier years (2023, 2020)

2023: $92

Payments by company in 2023
Genmab U.S.Epkinly$92
1 payment
  • Meals for Epkinly · 2023-06-03 · $92

2020: $3,634

Payments by company in 2020
Gilead SciencesNone$3,610
1 payment
  • Consulting · 2020-11-27 · $3,610
EisaiLenvima$24
1 payment
  • Meals for Lenvima · 2020-09-15 · $24

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Innate Pharma, Inc · Study of Iph2201 (Monalizumab) and Cetuximab in Patients With Recurrent Or Metastatic Squamous Cell Carcinoma of the Head and Neck · 2020Their institution$1,383,992
AbbVie Inc. · 2020Their institution$458,342
Coherus Oncology, Inc. · 2025Their institution$280,108
Coherus Biosciences Inc. · 2024Their institution$136,590
Merck Sharp & Dohme Corporation · An Open-Label Phase 1b,2 Study To Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-Pretreated, Recurrent,Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinomaallogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes Ata129 in Combination With Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Platinum-Resistant Or Refractory Ebv-Associated Nasopharyngeal Carcinoma · 2019Their institution$124,200
Gilead Sciences, Inc. · A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma · 2021Their institution$122,464
E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo · 2019Their institution$113,832
E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo · 2020Their institution$96,988
E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational · 2020Their institution$94,770
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184 in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2021Their institution$93,331
AbbVie, Inc. · 2019Their institution$90,407
BioNTech SE · 2022Their institution$82,896
Merck Sharp & Dohme LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of Cue-101 Monotherapy in Second Line Or Cue-101 Combination Therapy With Pembrolizumab in First Line Patients With Hpv Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma Hnscc · 2022Their institution$78,100
BioNTech SE · 2021Their institution$76,716
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2020Their institution$62,916
ABBVIE INC. · A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Abbv-368 As A Single Agent and Combination in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021Their institution$48,387
E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l (Registrational) - An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab Vs Therapy of Investigator'S Choice in Recurrent Or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (Scchn) · 2023Their institution$44,262
Incyte Corporation · Phase 2, Open-Label, Multicenter Study of Incagn01876 in Combination With Immunotherapy in Participants With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2023Their institution$43,488
AstraZeneca UK Limited · This Is A Randomized Open Label Multi Center Global Phase III Study To Determine the Efficacy and Safety of Medi4736 As Monotherapy and Medi4736 Tremelimumab Combination Therapy Versus Soc Therapy in the Target Patient Population · 2019Their institution$35,325
ABBVIE INC. · First in Human Study With Abbv-Cls-579 When Given Alone Or in Combination With Programmed Cell Death-1 Inhibitor in Participants With Locally Advanced Or Metastatic Tumors · 2024Their institution$32,438
Merck Sharp & Dohme LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of Cue-101 Monotherapy in Second Line Or Cue-101 Combination Therapy With Pembrolizumab in First Line Patients With Hpv Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma Hnscc · 2024Their institution$31,520
BioNTech SE · Pre-Commercial · 2023Their institution$27,633
Merck Sharp & Dohme Corporation · A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of Cue-101 Monotherapy in Second Line Or Cue-101 Combination Therapy With Pembrolizumab in First Line Patients With Hpv Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma Hnscc · 2020Their institution$26,000
E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational · 2019Their institution$21,327
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2022Their institution$19,635
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184 in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2019Their institution$17,278
BioNTech SE · 2024Their institution$14,336
E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo · 2021Their institution$12,328
E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational · 2021Their institution$9,550
E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational - An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab Vs Therapy of Investigator'S Choice in Recurrent Or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (Scchn) · 2022Their institution$6,165
E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic (Nivo/Chemo) - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin+Fluorouracil) As First Line Therapy in Recurrent Or M · 2023Their institution$5,056
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2023Their institution$4,800
ABBVIE INC. · A Study of the Safety, Tolerability and Pharmacokinetics of Abbv-368 As A Single Agent and Combination in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2023Their institution$2,560
Merck Sharp & Dohme LLC · An Open-Label Phase 1b,2 Study To Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-Pretreated, Recurrent,Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinomaallogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes Ata129 in Combination With Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Platinum-Resistant Or Refractory Ebv-Associated Nasopharyngeal Carcinoma · 2023Their institution$2,347
E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin+Fluorouracil) As First Line Therapy in Recurrent Or Met · 2022Their institution$2,036
E.R. Squibb & Sons, L.L.C. · Ph III 1l H&N Metastatic Nivo Chemo - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin+Fluorouracil) As First Line Therapy in Recurrent Or Metast · 2022Their institution$1,280
Merck Sharp & Dohme LLC · An Open-Label Phase 1b,2 Study To Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-Pretreated, Recurrent,Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinomaallogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes Ata129 in Combination With Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Platinum-Resistant Or Refractory Ebv-Associated Nasopharyngeal Carcinoma · 2021Their institution$784

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1588726558
Licence
CA C52711, MD D0041607California C52711: Current · expires 2026-11-30
Trained
Harvey Medical College
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
Yes
Taxonomy
Medical oncology (207RX0202X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address
300 Pasteur Dr, Palo Alto, CA, 94304
NPI first listed
2006-12-15
NPI last updated
2024-04-28
NPI record certified
2024-04-28

This is when the NPI record was last certified, not a medical board exam.